Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease

Core Insights - Viridian Therapeutics, Inc. announced positive topline data from the REVEAL-1 phase 3 clinical trial for elegrobart in patients with active thyroid eye disease (TED) [1] - Elegrobart is a subcutaneously delivered, half-life-extended monoclonal antibody targeting the insulin-like growth factor-1 receptor [1] Company Overview - Viridian Therapeutics focuses on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases [1]